Global pharma major Lupin Limited has announced its debut in the S&P Global Sustainability Yearbook 2024, underscoring its dedication to corporate sustainability.
With a notable Corporate Sustainability Assessment (CSA) score of 69/100, Lupin joins the ranks of leading companies recognized for their exemplary environmental, social, and governance (ESG) practices, the company said in a statement.
The S&P Global Sustainability Yearbook 2024, a benchmark for corporate sustainability performance, evaluated over 9400 companies worldwide, with only 739 earning inclusion. Lupin’s exceptional performance places it within the top 95 percentile for the pharmaceutical sector, showcasing its unwavering commitment to sustainable business practices.
“Lupin’s inclusion in the S&P Global Sustainability Yearbook 2024 underscores our firm commitment to advancing sustainable practices within the pharmaceutical industry. This recognition reaffirms our dedication to creating long-term value for all stakeholders while fostering a healthier, more sustainable future for generations to come. Lupin remains steadfast in its mission to prioritize sustainability, drive positive change, and make a meaningful difference in the world,” Ramesh Swaminathan, Executive Director, Global CFO and Head – Corporate Affairs, Lupin said.
